Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreVent-ACaLL: Acalabrutinib + Venetoclax in High-Risk CLL
NCT03868722Phase 3Recruiting
- Sponsor
- Rigshospitalet
- Start
- Oct 2019
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib and venetoclax in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Grade 3-Infection-free survival and Event-free survival at 2 years. Started Oct 2019; status: recruiting.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03868722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868722.